AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer

Abstract Background The receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR) is overexpressed and an important therapeutic target in Head and Neck cancer (HNC). Cetuximab is currently the only EGFR-targeting agent approved by the FDA for treatment of HNC; however, intrinsic and acq...

Full description

Bibliographic Details
Main Authors: Mari Iida, Nellie K. McDaniel, Kourtney L. Kostecki, Noah B. Welke, Carlene A. Kranjac, Peng Liu, Colin Longhurst, Justine Y. Bruce, Seungpyo Hong, Ravi Salgia, Deric L. Wheeler
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
AXL
neuregulin1
Head and neck cancer
Cetuximab
Resistance
HER3
Online Access:https://doi.org/10.1186/s12885-022-09511-6

Internet

https://doi.org/10.1186/s12885-022-09511-6

Similar Items